| NCT ID | NCT01102569 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Columbia University |
| Condition | Pancreatic Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 100 participants |
| Start Date | 2008-01 |
| Primary Completion | 2026-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 100 participants in total. It began in 2008-01 with a primary completion date of 2026-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The aim of this study is to determine the frequency of the three most common BReast CAncer gene 1 (BRCA1) and BReast CAncer gene 2 (BRCA2) genetic mutations that are commonly found in Ashkenazi Jewish patients with pancreatic cancer. Testing for BRCA1 and BRCA2 mutations in relatives of hereditary pancreatic cancer patients may have a significant impact; allowing for early screening, treatment, and resection of pre-malignant tissue or malignant lesions.
Eligibility Criteria
Inclusion Criteria: * Patients diagnosed with pancreatic cancer. * Patients are of Ashkenazi Jewish descent. * Patients have been Columbia Pancreatic Cancer Prevention Program Registry and Tissue Bank for High-Risk Individuals (IRB-AAAA6154). Exclusion Criteria: * Inability to provide informed consent. * Under the age of 18 years old.
Contact & Investigator
Fay Kastrinos, MD
PRINCIPAL INVESTIGATOR
Columbia University
Frequently Asked Questions
Who can join the NCT01102569 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 85 Years, studying Pancreatic Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT01102569 currently recruiting?
Yes, NCT01102569 is actively recruiting participants. Contact the research team at fk18@columbia.edu for enrollment information.
Where is the NCT01102569 trial being conducted?
This trial is being conducted at New York, United States.
Who is sponsoring the NCT01102569 clinical trial?
NCT01102569 is sponsored by Columbia University. The principal investigator is Fay Kastrinos, MD at Columbia University. The trial plans to enroll 100 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.